)
)
)
Quince Therapeutics
Quince Therapeutics is a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases. By pioneering the encapsulation of drugs in a patient’s own red blood cells, we seek to advance proprietary therapeutics that hold the potential to redefine the standard of care and meaningfully improve the quality of life for patients with rare disease. Our lead asset, eDSP, has completed enrollment in a Phase 3 trial for the treatment of a rare pediatric neurodegenerative disease, Ataxia-Telangiectasia, with topline data read out in Q1 2026. Additionally, we plan to initiate a P2 study in 2026 with eDSP in DMD.
Address
South San FranciscoCA
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)